مباشر
FierceBiotechHow RA Capital is offering its biotechs ‘Chinese clinical expertise in a box’Endpoints NewsNovo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial execBioPharma DivePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?Lonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma LetterCellSingle-cell mapping of regulatory DNA-protein interactionsCellPlasma signals of lung tumor promotion for molecular cancer preventionCellDeep learning of functional perturbations from condensate morphologyFierceBiotechAt first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from expertsLonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter10x Genomics Blog10x Genomics Stock On Fire: Up 41% With 8-Day Winning Streak - TrefisLabiotechEpisode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech mediaLonza NewsLonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies - Indian Pharma Post
Roche Media ١٠ ديسمبر ٢٠٢٥

Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial - Fierce Biotech

Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial - Fierce Biotech

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.